CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 74 enrolled
Drug / intervention
sitagliptin OR saxagliptin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02377388
NCT02377388Phase 3Completed
CompareCT.gov

DPP-4 Inhibitors in Patients With Type 2 Diabetes and Acute Myocardial Infarction:Effects on Platelet Function

University of Sao Paulo General Hospital·interventional·Posted Mar 3, 2015·Updated Aug 28, 2020

In Brief

A Phase 3 clinical trial evaluating sitagliptin OR saxagliptin and placebo for Platelet Aggregation During Acute Myocardial Infarction. Completed, enrolled 74 participants across 1 site.

Detailed Summary

Cardiovascular events are the main cause of mortality in diabetic patients ,on the other hand,during an acute myocardial infarction(AMI),hyperglycemia increases mortality and is related to different pathophysiologic processes. More important evidence regarding the effect of glycemic control on AMI patients prognosis is contradictory,and the potential benefits of dipeptidyl peptidase-4 inhibitors(DPP4-i) in this setting is unknown. The aim of this study is to assess the presence of pleiotropic effects of DPP4-i(sitagliptin or saxagliptin) and their relationship with glycemic control during in-hospital phase of AMI.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlatelet Aggregation During Acute Myocardial Infarction
CountriesBrazil
CollaboratorsInCor Heart Institute

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 3, 2015
Enrollment StartFeb 7, 2017
Primary CompletionFeb 28, 2020
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 11.3 years ago

Interventions

sitagliptin OR saxagliptindrug

sitagliptin OR saxagliptin tablets, 48(+-24) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .

placebodrug

placebo tablets, 48(+-24) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .